Tag: Abbott

Abbott Announces Start of Trial to Evaluate the New Esprit™ BTK Drug-Eluting Resorbable Scaffold

– The LIFE-BTK trial will evaluate the company’s new drug-eluting resorbable scaffold (DRS), known as the Esprit BTK System, for the treatment of blocked arteries below-the-knee (BTK) – Esprit BTK was granted breakthrough device designation by the U.S. FDA – There are no stents or drug-coated balloons currently approved for […]

Abbott Announces Start of Study to Evaluate New Device to Treat Recurrent Atrial Fibrillation

– Recurrent irregular heartbeat–also known as atrial fibrillation–impacts more than 16 million people globally – Trial supports Abbott’s focus on being the best partner for electrophysiologists treating people living with atrial fibrillation ABBOTT PARK, Ill., Aug. 4, 2020 /PRNewswire/ — Abbott (NYSE: ABT) today announced first enrollments in the TactiFlex PAF IDE study to […]

Abbott Agrees to Global Transcatheter Litigation Settlement with Edwards Lifesciences

ABBOTT PARK, Ill., July 13, 2020 /PRNewswire/ — Abbott (NYSE: ABT) announced today it has reached an agreement with Edwards Lifesciences Corporation to settle all outstanding patent disputes between the companies in cases related to transcatheter mitral and tricuspid repair products. The agreement will result in the dismissal of all pending cases or appeals […]

Abbott Receives FDA Approval for New Heart Rhythm Devices Featuring Bluetooth Connectivity and Continuous Remote Monitoring

ABBOTT PARK, Ill., July 6, 2020 /PRNewswire/ — Abbott (NYSE: ABT) today announced that the U.S. Food and Drug Administration (FDA) has approved the company’s next-generation Gallant™ implantable cardioverter defibrillator (ICD) and cardiac resynchronization therapy defibrillator (CRT-D) devices. The devices bring new benefits to patients with heart rhythm disorders, including […]

New Research Finds Abbott’s Optical Coherence Tomography Imaging Changed Treatment Decisions in 88% of Artery Blockages

— Using optical coherence tomography (OCT)-guided percutaneous coronary intervention (PCI), physicians were able to select the right size stents and place them with greater precision — Imaging techniques such as OCT have been shown to improve outcomes during stenting procedures¹, but remain underutilized in global clinical settings due to lack […]

New Late-Breaking Data Highlight Impact of Abbott’s Minimally Invasive Structural Heart Therapies

– New data reinforce Abbott’s leadership in minimally invasive treatment options for mitral and tricuspid repair and replacement therapies – Eleven late-breaking presentations at the PCR e-Course showcase impact of Abbott’s innovative structural heart portfolio on patient outcomes and quality of life in real-world and clinical settings ABBOTT PARK, Ill., June […]

ABBOTT REPORTS FIRST-QUARTER 2020 RESULTS

– First-quarter sales growth of 2.5 percent; organic sales growth of 4.3 percent – Recently launched three breakthrough diagnostics tests for coronavirus (COVID-19) ABBOTT PARK, Ill., April 16, 2020 /PRNewswire/ — Abbott (NYSE: ABT) today announced financial results for the first quarter ended March 31, 2020. First-quarter worldwide sales of $7.7 billion increased 2.5 percent on […]

ABBOTT’S TRICLIP™ BECOMES FIRST DEVICE OF ITS KIND TO RECEIVE CE MARK FOR MINIMALLY INVASIVE TRICUSPID VALVE REPAIR

– CE Mark for TriClip represents an important treatment option for people with severe tricuspid regurgitation, a difficult-to-manage heart condition – New system offers a proven safe and effective minimally invasive non-surgical solution – The TriClip System leverages Abbott’s proven clip-based technology used in its MitraClip™ transcatheter mitral valve therapy […]

Abbott Aims to Optimize TAVI Implants with European Approval of FlexNav™ Delivery System for the Company’s Portico™ Valve

– New FlexNav™ delivery system improves control and delivery of the Portico™ TAVI valve even in complex clinical cases – The minimally invasive Portico procedure allows doctors to treat severe aortic valve stenosis without invasive surgery – Approval of the new delivery system follows first implants of the company’s next-generation […]

Abbott Introduces Next-Generation Heart Rhythm Management Devices in Europe, Featuring State-of-the-Art Patient App and Bluetooth Connectivity

– New Gallant™ high voltage devices offer patients and their doctors a smartphone app and Bluetooth connectivity designed to help doctors tailor therapy to a patient’s unique clinical needs – Gallant ICD and CRT-D devices feature a more comfortable design, preferred by patients without compromising on battery longevity or high-voltage […]